Sign up to save your podcasts
Or
Share Episode 387: ASCO GU 2025 -Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: updated efficacy and safety results
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Episode 387: ASCO GU 2025 -Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: updated efficacy and safety results
Xinan Sheng. M.D., Professor in the Department of Genitourinary Oncology at Peking University Cancer Hospital &institute in Beijing, China joins us to discuss the update of this trial and impressive pCR rates.
View all episodes
By The Uromigos
4.9
5555 ratings
Xinan Sheng. M.D., Professor in the Department of Genitourinary Oncology at Peking University Cancer Hospital &institute in Beijing, China joins us to discuss the update of this trial and impressive pCR rates.
More shows like The Uromigos
View all
JAMA Editors' Summary
135 Listeners
Prostate Cancer Update
14 Listeners
NEJM This Week
319 Listeners
JAMA Clinical Reviews
503 Listeners
AFP: American Family Physician Podcast
693 Listeners
ASCO Daily News
59 Listeners
White Coat Investor Podcast
2,422 Listeners
The Curbsiders Internal Medicine Podcast
3,327 Listeners
The Peter Attia Drive
8,025 Listeners
Annals On Call Podcast
196 Listeners
The Clinical Problem Solvers
519 Listeners
GU Cast | Urology Podcast
2 Listeners
BioCentury This Week
30 Listeners
Two Onc Docs
181 Listeners
The View on GU | with Lalani and Wallis
2 Listeners